However, subsequent generation of a bsAb against EphA2 and EphA3 showed that even unconjugated antibody was effective in reducing stem cell clonogenicity in vitro, and tumor burden of recurrent GBM xenografts in vivo [51]. The gene discussed is EPHA3; the disease is glioblastoma.